Terms: = Endocrine gland cancer AND NFKB2, ENSG00000077150, LYT10, LYT-10, 4791 AND Treatment
4 results:
1. Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
Kallio HM; Savolainen K; Virtanen T; Ryyppö L; Selin H; Martikainen P; Staff S; Kivinummi K; Sipola J; Vuorinen J; Nikkola J; Nykter M; Auranen A; Annala M
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38580393
[TBL] [Abstract] [Full Text] [Related]
2. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The cancer Genome Atlas.
Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
[TBL] [Abstract] [Full Text] [Related]
3. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis.
Guo J; Wang W; Liao P; Lou W; Ji Y; Zhang C; Wu J; Zhang S
Cancer Sci; 2009 Dec; 100(12):2292-301. PubMed ID: 19775290
[TBL] [Abstract] [Full Text] [Related]
4. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract] [Full Text] [Related]
